Cumulative incidence of second active treatment or death by frontline active treatment∗
| . | 12-mo Cum. Inc. (95% CI) . | 24-mo Cum. Inc. (95% CI) . | 36-mo Cum. Inc. (95% CI) . | 60-mo Cum. Inc. (95% CI) . | P value . |
|---|---|---|---|---|---|
| First active treatment | 0.22 (0.15-0.33) | 0.31 (0.22-0.43) | 0.37 (0.27-0.49) | 0.37 (0.27-0.49) | .02 |
| Radiation | 0 | 0.06 (0.01-0.39) | 0.11 (0.03-0.44) | 0.11 (0.03-0.44) | |
| Anti-CD20 mAb | 0.31 (0.17-0.57) | 0.44 (0.28-0.7) | 0.53 (0.36-0.78) | 0.53 (0.36-0.78) | |
| Chemoimmunotherapy | 0.26 (0.16-0.44) | 0.34 (0.22-0.53) | 0.37 (0.25-0.56) | 0.37 (0.25-0.56) | |
| Death | 0.03 (0.01-0.11) | 0.03 (0.01-0.11) | 0.03 (0.01-0.11) | 0.05 (0.02-0.14) | .07 |
| Radiation | 0 | 0 | 0 | 0 | |
| Anti-CD20 mAb | 0.04 (0.01-0.29) | 0.04 (0.01-0.29) | 0.04 (0.01-0.29) | 0.09 (0.02-0.38) | |
| Chemoimmunotherapy | 0.05 (0.01-0.18) | 0.05 (0.01-0.18) | 0.05 (0.01-0.18) | 0.05 (0.01-0.18) |
| . | 12-mo Cum. Inc. (95% CI) . | 24-mo Cum. Inc. (95% CI) . | 36-mo Cum. Inc. (95% CI) . | 60-mo Cum. Inc. (95% CI) . | P value . |
|---|---|---|---|---|---|
| First active treatment | 0.22 (0.15-0.33) | 0.31 (0.22-0.43) | 0.37 (0.27-0.49) | 0.37 (0.27-0.49) | .02 |
| Radiation | 0 | 0.06 (0.01-0.39) | 0.11 (0.03-0.44) | 0.11 (0.03-0.44) | |
| Anti-CD20 mAb | 0.31 (0.17-0.57) | 0.44 (0.28-0.7) | 0.53 (0.36-0.78) | 0.53 (0.36-0.78) | |
| Chemoimmunotherapy | 0.26 (0.16-0.44) | 0.34 (0.22-0.53) | 0.37 (0.25-0.56) | 0.37 (0.25-0.56) | |
| Death | 0.03 (0.01-0.11) | 0.03 (0.01-0.11) | 0.03 (0.01-0.11) | 0.05 (0.02-0.14) | .07 |
| Radiation | 0 | 0 | 0 | 0 | |
| Anti-CD20 mAb | 0.04 (0.01-0.29) | 0.04 (0.01-0.29) | 0.04 (0.01-0.29) | 0.09 (0.02-0.38) | |
| Chemoimmunotherapy | 0.05 (0.01-0.18) | 0.05 (0.01-0.18) | 0.05 (0.01-0.18) | 0.05 (0.01-0.18) |
Cum. Inc., cumulative incidence.
The bold values are statistically significant (p values less than 0.05).
Patients with observation or “other” as initial management strategy were excluded from this analysis.